Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate and Glasdegib

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Cobicistat may significantly increase the blood levels of glasdegib. High levels of glasdegib can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). The risk and/or severity of other side effects may also increase, including nausea, decreased appetite, constipation, mouth sores, muscle pain, shortness of breath, swelling of arms or legs, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or fever and infections due to low blood cell counts. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with glasdegib. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of glasdegib, which is primarily metabolized by the isoenzyme. When glasdegib was coadministered with ketoconazole, a potent CYP450 3A4 inhibitor, glasdegib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 1.4- and 2.4-fold, respectively, compared to administration of glasdegib alone. Increased exposure to glasdegib may increase the risk of serious adverse effects such as QT interval prolongation, anemia, febrile neutropenia, thrombocytopenia, hemorrhage, edema, and mucositis.

MANAGEMENT: Concomitant use of glasdegib with potent CYP450 3A4 inhibitors should generally be avoided. Alternative agents with no or minimal CYP450 3A4 inhibitory potential are recommended whenever possible. Otherwise, close monitoring for increased adverse effects is advisable, including more frequent ECG monitoring.

Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate

Generic Name: cobicistat / elvitegravir / emtricitabine / tenofovir

Brand name: Genvoya, Stribild

Synonyms: Cobicistat, elvitegravir, emtricitabine, and tenofovir

What is Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate?

Glasdegib

Generic Name: glasdegib

Brand name: Daurismo

Synonyms: n.a.

What is Glasdegib?